David Quigley

Akin Gump Strauss Hauer & Feld LLP

+ Follow Contact

Latest Posts › Food and Drug Administration (FDA)

Share:

FDA Moves Forward on Fluoropolymers

On August 6, 2025, the U.S. Food and Drug Administration (FDA) became the latest governmental agency to confirm that fluoropolymers are both safe and necessary. After an independent safety review of fluoropolymers in medical...more

8/7/2025 / Food and Drug Administration (FDA) , Healthcare , Life Sciences , Manufacturers , Medical Devices , Medical Technology Companies , PFAS , Regulatory Oversight , Regulatory Requirements , Risk Assessment

PFAS Ground Zero Revisited: Checking in on Maine and Minnesota

In many ways, Maine and Minnesota had the first words on the regulation of PFAS in the U.S. Their broad definitions of the chemicals set the stage for similar regulation across the continent. So when legislators in both...more

3/11/2025 / Environmental Policies , Food and Drug Administration (FDA) , Legislative Agendas , New Legislation , PFAS , Proposed Legislation , Regulatory Agenda , Regulatory Requirements , State and Local Government , Toxic Chemicals

EPA IG's Concerns About Oversight of Hospital Disinfectants Reinforces Need for Robust Infection Control Programs

On September 19, 2016, the Inspector General (IG) for the Environmental Protection Agency (EPA) issued the latest in a long line of reports identifying flaws in EPA’s process for ensuring the efficacy of hospital-grade,...more

9/23/2016 / Chemicals , Environmental Protection Agency (EPA) , Food and Drug Administration (FDA) , GAO , Healthcare Facilities , Hospitals , Infectious Diseases , Inspector General , Public Health , Public Safety

3 Results

View per page

Page: of 1